NZ710875A - Composition of tiacumicin compounds - Google Patents

Composition of tiacumicin compounds

Info

Publication number
NZ710875A
NZ710875A NZ71087514A NZ71087514A NZ710875A NZ 710875 A NZ710875 A NZ 710875A NZ 71087514 A NZ71087514 A NZ 71087514A NZ 71087514 A NZ71087514 A NZ 71087514A NZ 710875 A NZ710875 A NZ 710875A
Authority
NZ
New Zealand
Prior art keywords
composition
polymorph
carrageenan
solvate
isomer
Prior art date
Application number
NZ71087514A
Other languages
English (en)
Inventor
Yoshiyuki Murakami
Hikaru Saito
Original Assignee
Astellas Pharma Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47563169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ710875(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Europe Ltd filed Critical Astellas Pharma Europe Ltd
Publication of NZ710875A publication Critical patent/NZ710875A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ71087514A 2013-01-15 2014-01-14 Composition of tiacumicin compounds NZ710875A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13075002 2013-01-15
PCT/EP2014/000091 WO2014111254A1 (en) 2013-01-15 2014-01-14 Composition of tiacumicin compounds

Publications (1)

Publication Number Publication Date
NZ710875A true NZ710875A (en) 2019-10-25

Family

ID=47563169

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ71087514A NZ710875A (en) 2013-01-15 2014-01-14 Composition of tiacumicin compounds

Country Status (28)

Country Link
US (1) US9808530B2 (enExample)
EP (1) EP2945613B1 (enExample)
JP (1) JP6338598B2 (enExample)
KR (1) KR102181474B1 (enExample)
CN (1) CN105120840B (enExample)
AR (1) AR094495A1 (enExample)
AU (1) AU2014207083B2 (enExample)
CA (1) CA2904808A1 (enExample)
CY (1) CY1121459T1 (enExample)
DK (1) DK2945613T3 (enExample)
EA (1) EA030049B1 (enExample)
ES (1) ES2705238T3 (enExample)
GE (1) GEP201706769B (enExample)
HR (1) HRP20182110T1 (enExample)
HU (1) HUE041421T2 (enExample)
IL (1) IL239899A0 (enExample)
JO (1) JO3464B1 (enExample)
LT (1) LT2945613T (enExample)
MD (1) MD4588C1 (enExample)
NZ (1) NZ710875A (enExample)
PL (1) PL2945613T3 (enExample)
PT (1) PT2945613T (enExample)
RS (1) RS58119B1 (enExample)
SI (1) SI2945613T1 (enExample)
TW (1) TWI646962B (enExample)
UA (1) UA117004C2 (enExample)
WO (1) WO2014111254A1 (enExample)
ZA (1) ZA201505048B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015169451A1 (en) 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound
CN110037992B (zh) * 2019-05-28 2021-05-28 杭州华东医药集团新药研究院有限公司 一种稳定的非达霉素组合物
CN116715678B (zh) * 2023-06-12 2025-09-30 中国科学院成都生物研究所 一种吲哚糖碳苷类大环化合物及其制备方法与应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3000792A (en) 1957-05-21 1961-09-19 Merck & Co Inc Antibiotic adsorption process
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4632902A (en) 1981-08-20 1986-12-30 Becton, Dickinson And Company Method for detecting biological activity in a body fluid
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
CA2384529C (en) 1991-03-04 2007-01-02 Bayer Corporation Automated analyzer
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
ATE267197T1 (de) 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
WO2001083800A2 (en) 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Heterologous production of polyketides
WO2002032427A1 (en) 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
US7507564B2 (en) 2002-07-29 2009-03-24 Optimer Pharmaceuticals, Inc. Tiacumicin production
WO2006085838A1 (en) 2005-01-31 2006-08-17 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20040224020A1 (en) 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2005009474A1 (ja) 2003-07-24 2005-02-03 Shionogi & Co., Ltd. 難水溶性薬物を含むドライシロップ剤
JP3881640B2 (ja) 2003-08-08 2007-02-14 塩野義製薬株式会社 ロラタジンを含むドライシロップ剤
ES2395404T3 (es) 2004-05-14 2013-02-12 Optimer Pharmaceuticals, Inc. Tratamiento de las enfermedades asociadas al uso de antibióticos
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US8586551B2 (en) 2005-01-31 2013-11-19 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
CA2626698C (en) 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US20080176927A1 (en) * 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JP5608880B2 (ja) * 2010-02-09 2014-10-22 林兼産業株式会社 嚥下困難者用高栄養ゼリー食品
CN102030791B (zh) 2010-10-28 2013-01-23 中国科学院南海海洋研究所 四种台勾霉素类化合物及其制备方法和在制备抗菌药物中的应用
CN102115757B (zh) 2010-12-14 2015-10-28 中国科学院南海海洋研究所 台勾霉素的生物合成基因簇及其应用

Also Published As

Publication number Publication date
PT2945613T (pt) 2019-01-17
SI2945613T1 (sl) 2019-02-28
CA2904808A1 (en) 2014-07-24
MD4588C1 (ro) 2019-03-31
ES2705238T3 (es) 2019-03-22
DK2945613T3 (en) 2019-01-14
CN105120840A (zh) 2015-12-02
JP6338598B2 (ja) 2018-06-06
US20160045603A1 (en) 2016-02-18
HRP20182110T1 (hr) 2019-02-22
ZA201505048B (en) 2020-05-27
MD4588B1 (ro) 2018-08-31
EP2945613B1 (en) 2018-10-10
AU2014207083A1 (en) 2015-08-27
IL239899A0 (en) 2015-08-31
RS58119B1 (sr) 2019-02-28
GEP201706769B (en) 2017-11-10
US9808530B2 (en) 2017-11-07
KR102181474B1 (ko) 2020-11-23
EA030049B1 (ru) 2018-06-29
EP2945613A1 (en) 2015-11-25
CN105120840B (zh) 2019-03-22
WO2014111254A1 (en) 2014-07-24
PL2945613T3 (pl) 2019-05-31
JP2016505026A (ja) 2016-02-18
HUE041421T2 (hu) 2019-05-28
EA201591226A1 (ru) 2016-01-29
JO3464B1 (ar) 2020-07-05
TW201440775A (zh) 2014-11-01
AR094495A1 (es) 2015-08-05
UA117004C2 (uk) 2018-06-11
KR20150114498A (ko) 2015-10-12
LT2945613T (lt) 2019-01-10
AU2014207083B2 (en) 2018-03-29
MD20150070A2 (ro) 2016-01-31
CY1121459T1 (el) 2020-05-29
TWI646962B (zh) 2019-01-11

Similar Documents

Publication Publication Date Title
SI2958913T1 (sl) Sfingozin-1-fosfat receptor agonisti, postopki za njegovo pripravo in farmacevtski sestavki, ki ga vsebujejo kot aktivno sredstvo
JO3773B1 (ar) معدلات p2x7
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
PH12016500170A1 (en) Formulation of syk inhibitors
MX350447B (es) Composicion farmaceutica de disolucion rapida.
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
NZ711982A (en) Cytotoxic and anti-mitotic compounds, and methods of using the same
SA112330855B1 (ar) تركيبة صيدلانية سريعة الذوبان
PH12015502178A1 (en) Pyridinylpyrazoloquinoline compound
UA116395C2 (uk) ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
UA115357C2 (uk) Похідні піридин-4-ілу
MX2013006418A (es) Derivados de oxazolil-metileter como agonistas del receptor de alx.
NZ628962A (en) Stabilisation of fsh
WO2014153495A3 (en) Novel stat3 inhibitors
IN2014DN10669A (enExample)
JO3464B1 (ar) التركيبات الخاصة بمركبات التياكوميسين
PH12015501643A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
MX2016005160A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
PH12016500809B1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
WO2015102017A8 (en) Processes for the preparation of lorcaserin
IN2013MU03309A (enExample)
IN2013MU03422A (enExample)
UA88421U (ru) Фармацевтическая композиция "фузипан-дерма" для лечения угревой болезни i-ii стадий
MX2023006909A (es) Metodos de uso de compuestos de fenoxipropilamina para tratar la depresion.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20201218

LAPS Patent lapsed